Panacea Biotec

The company confirms the conclusion of Narotam Kumar Juneja’s tenure as Non-Executive Non-Independent Director and Whole-Time…

Both the entities have entered into definitive agreements for the transaction involving a complete consideration of Rs 1,872…

Under the terms of the funding agreement, THSTI and Panacea Biotec have committed to achieve equitable access to the outputs of…

Doses of the second component of Sputnik V have been manufactured at the Panacea Biotec’s state-of-the-art vaccine manufacturing…

Sputnik V was registered in India under the emergency use authorisation procedure on April 12, 2021, and vaccination against…

RDIF and Panacea have agreed to produce 100 million doses per year of Sputnik V

He had a 5.15 per cent shareholding in the company and the total value of the transaction was a little over Rs 118 crores

The Russian Direct Investment Fund (RDIF) and Panacea Biotec announce cooperation to produce 100 million doses per year of…

The company informs that it is in the process of providing a thorough and comprehensive response to the USFDA within the statutory…

The company has approached DGCI to seek accelerated review of its data to bring DengiAIl to market quickly